L1920
LY255283
≥98% (HPLC), powder
别名:
1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H28N4O3
化学文摘社编号:
分子量:
360.45
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
产品名称
LY255283, ≥98% (HPLC), powder
InChI
1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)
SMILES string
CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2
InChI key
WCGXJPFHTHQNJL-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
off-white to light yellow
solubility
DMSO: >20 mg/mL
originator
Eli Lilly
storage temp.
−20°C
Quality Level
Application
LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils. LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.
Biochem/physiol Actions
LY255283 is a competitive leukotriene B4 receptor antagonist, specific to the BLT2 receptor subtype.
LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC50 values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.
Features and Benefits
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Jin-Wook Lee et al.
The Journal of biological chemistry, 288(42), 30054-30063 (2013-08-30)
The majority of prostate cancer-related deaths are associated with advanced and metastatic malignancies. Although anoikis resistance has been recognized as one of the hallmarks of metastatic prostate malignancies, the molecular events that cause anoikis resistance are poorly understood. In this
J Wijkander et al.
The Journal of biological chemistry, 270(44), 26543-26549 (1995-11-03)
Addition of submicromolar concentrations of arachidonic acid (AA) to human neutrophils induced a 2-fold increase in the activity of a cytosolic phospholipase A2 (PLA2) when measured using sonicated vesicles of 1-stearoyl-2-[14C]arachidonoylphosphatidylcholine as substrate. A similar increase in cytosolic PLA2 activity
P S Wollert et al.
Surgery, 114(2), 191-198 (1993-08-01)
Polymorphonuclear neutrophils (PMNs) have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). Because leukotriene B4 (LTB4) is a potent activator of PMNs, we sought to determine whether LY255283, an LTB4 receptor antagonist, could block PMN activation
Anne-Sofie Johansson et al.
Prostaglandins, leukotrienes, and essential fatty acids, 84(3-4), 109-112 (2010-12-25)
Leukotriene B4 (LTB4), a potent chemotactic and immune-modulating lipid mediator, signals via two receptors, BLT1 and BLT2, leading to pro-inflammatory responses in phagocytes. Recently, we reported that BLT1 is the predominating BLT on human umbilical vein endothelial cells (HUVEC) and
J S Sawyer et al.
Journal of medicinal chemistry, 38(22), 4411-4432 (1995-10-27)
Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持